
First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 product candidate Three clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine® IMA200 trial series Immatics N.V. […]